Financials in USD. Standardized financial statements.
A compact view of how Hikma Pharmaceuticals PLC turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.36B | $3.13B | $2.88B | $2.52B | $2.55B | $2.34B | $2.21B | $2.07B | $1.94B | $1.95B |
| Revenue Growth? | +7.3% | +8.8% | +14.2% | -1.4% | +9.1% | +6.1% | +6.6% | +6.9% | -0.7% | 0.0% |
| Cost of Revenue? | $2.01B | $1.71B | $1.47B | $1.28B | $1.25B | $1.14B | $1.06B | $1.02B | $969.00M | $964.00M |
| Gross Profit? | $1.34B | $1.42B | $1.41B | $1.24B | $1.30B | $1.20B | $1.15B | $1.05B | $967.00M | $986.00M |
| Gross Margin? | +40.0% | +45.3% | +48.9% | +49.2% | +51.0% | +51.3% | +52.0% | +50.7% | +49.9% | +50.6% |
| Operating Expenses? | $718.68M | $803.00M | $1.04B | $956.00M | $719.00M | $622.00M | $655.00M | $690.00M | $635.00M | $611.00M |
| Operating Income? | $625.46M | $612.00M | $367.00M | $282.00M | $582.00M | $579.00M | $493.00M | $371.00M | -$747.00M | $302.00M |
| EBITDA? | $837.95M | $727.00M | $559.00M | $688.00M | $766.00M | $747.00M | $660.00M | $456.00M | -$543.00M | $383.00M |
| Income Before Tax | $520.21M | $454.00M | $281.00M | $233.00M | $543.00M | $558.00M | $491.00M | $293.00M | -$738.00M | $210.00M |
| Income Tax Expense | $112.26M | $93.00M | $89.00M | $42.00M | $124.00M | $128.00M | $4.00M | $8.00M | $101.00M | $52.00M |
| Net Income? | $402.94M | $359.00M | $190.00M | $188.00M | $421.00M | $431.00M | $486.00M | $282.00M | -$843.00M | $155.00M |
| EPS? | $3.66 | $3.24 | $1.70 | $1.68 | $3.64 | $3.66 | $4.02 | $2.34 | $-7.02 | $1.34 |
| Diluted EPS? | $3.62 | $3.22 | $1.72 | $1.68 | $3.62 | $3.62 | $4.00 | $2.34 | $-7.02 | $1.32 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality